AstraZeneca has reported the first phase 3 data with its next-generation complement C5 inhibitor, gefurulimab, which could give patients with generalised myasthenia gravis (gMG) a treatment option ...

Johnson & Johnson's Imaavy has become the first FcRn blocker to be approved in the EU as a treatment for both adolescent and adult patients with generalised myasthenia gravis (gMG), taking on rivals ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Graphene Manufacturing Group Ltd, a clean-technology company, engages in the manufacture of graphene powder and energy saving and energy storage solutions enabled by graphene in Australia. The company ...